MedTrace Logo

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

NCT05936489 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-10-16

No results posted yet for this study

Summary

This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.

Conditions

  • Eye Diseases
  • Presbyopia
  • Refractive Errors
  • Brimonidine Tartrate
  • Aceclidine
  • Ophthalmic Solutions

Interventions

DRUG

Aceclidine + Brimonidine

LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution

DRUG

Aceclidine

LNZ100 (Aceclidine) non-preserved ophthalmic solution

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • LENZ Therapeutics, Inc

    lead OTHER

Principal Investigators

  • Kris Gameblin · LENZ Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2023-10-03
Completion
2023-10-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05936489 on ClinicalTrials.gov